Foreword-new directions for Topotecan in lung cancer treatment

Oncologist

Volumn 9, Issue SUPPL. 6, 2004, Pages 1-3

  Stewart, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Non small cell lung cancer; Quality of life; Small cell lung cancer; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

ARTICLE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; QUALITY OF LIFE; SMALL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; TOPOTECAN;

EID: 16644385521     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90006-1     Document Type: Editorial

References (8)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543. Erratum in; Lancet Oncol 2001;2:596.
2. American Cancer Society. Cancer Facts and Figures 2004. http://www.cancer.org/downloads/STT/CAFF_finalIPWSecured.pdf, accessed 08/02/04
3. Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: an update. The Oncologist 2004;9(suppl6):4-13
4. von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristime for the treatment of recurrent small cell lung cancer. J Clin Oncol 1999;17:658-667.
5. Eckardt JR. Emerging role of weekly topotecan in recurrent small cell lung cancer. The Oncologist 20049(suppl 6):25-32.
6. Gralla RJ. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. The Oncologist 2004;9(suppl 6):14-24.
7. Stewart DJ. Topotecan in the first-line treatment of small cell lung cancer. The Oncologist 2004;9(suppl 6):33-42.
8. Stewart DJ. Update on the role of topotecan in the treatment of non-small cell lung cancer. The Oncologist 2004;9(suppl 6): 43-52.